201 related articles for article (PubMed ID: 16333677)
1. Liposome formulation of a novel hydrophobic aryl-imidazole compound for anti-cancer therapy.
Liu J; Lee H; Huesca M; Young A; Allen C
Cancer Chemother Pharmacol; 2006 Sep; 58(3):306-18. PubMed ID: 16333677
[TBL] [Abstract][Full Text] [Related]
2. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies.
Nallamothu R; Wood GC; Kiani MF; Moore BM; Horton FP; Thoma LA
PDA J Pharm Sci Technol; 2006; 60(3):144-55. PubMed ID: 17089683
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S
J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116
[TBL] [Abstract][Full Text] [Related]
4. Mixed micelles of lipoic acid-chitosan-poly(ethylene glycol) and distearoylphosphatidylethanolamine-poly(ethylene glycol) for tumor delivery.
Elsaid Z; Taylor KM; Puri S; Eberlein CA; Al-Jamal K; Bai J; Klippstein R; Wang JT; Forbes B; Chana J; Somavarapu S
Eur J Pharm Sci; 2017 Apr; 101():228-242. PubMed ID: 28163163
[TBL] [Abstract][Full Text] [Related]
5. Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.
Gholizadeh S; Dolman EM; Wieriks R; Sparidans RW; Hennink WE; Kok RJ
Pharm Res; 2018 Mar; 35(4):85. PubMed ID: 29516187
[TBL] [Abstract][Full Text] [Related]
6. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
[TBL] [Abstract][Full Text] [Related]
7. Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity.
Shmeeda H; Amitay Y; Tzemach D; Gorin J; Gabizon A
J Control Release; 2013 May; 167(3):265-75. PubMed ID: 23419948
[TBL] [Abstract][Full Text] [Related]
8. PEGylated Liposomes of Meloxicam: Optimization by Quality by Design, in vitro Characterization and Cytotoxicity Evaluation.
Shaji J; Menon I
Pharm Nanotechnol; 2017; 5(2):119-137. PubMed ID: 28462699
[TBL] [Abstract][Full Text] [Related]
9. Formulation and optimization of idarubicin thermosensitive liposomes provides ultrafast triggered release at mild hyperthermia and improves tumor response.
Lu T; Lokerse WJM; Seynhaeve ALB; Koning GA; Ten Hagen TLM
J Control Release; 2015 Dec; 220(Pt A):425-437. PubMed ID: 26541464
[TBL] [Abstract][Full Text] [Related]
10. Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes.
Dos Santos N; Mayer LD; Abraham SA; Gallagher RC; Cox KA; Tardi PG; Bally MB
Biochim Biophys Acta; 2002 Apr; 1561(2):188-201. PubMed ID: 11997119
[TBL] [Abstract][Full Text] [Related]
11. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S
Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877
[TBL] [Abstract][Full Text] [Related]
12. Lyophilization of cholesterol-free PEGylated liposomes and its impact on drug loading by passive equilibration.
Chaudhury A; Das S; Lee RF; Tan KB; Ng WK; Tan RB; Chiu GN
Int J Pharm; 2012 Jul; 430(1-2):167-75. PubMed ID: 22537806
[TBL] [Abstract][Full Text] [Related]
13. In vivo antitumor activity of cis-bis-neodecanoato-trans-R,R-1, 2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes.
Mori A; Wu SP; Han I; Khokhar AR; Perez-Soler R; Huang L
Cancer Chemother Pharmacol; 1996; 37(5):435-44. PubMed ID: 8599866
[TBL] [Abstract][Full Text] [Related]
14. Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo.
Cai L; Wang X; Wang W; Qiu N; Wen J; Duan X; Li X; Chen X; Yang L; Qian Z; Wei Y; Chen L
Int J Nanomedicine; 2012; 7():4499-510. PubMed ID: 22923988
[TBL] [Abstract][Full Text] [Related]
15. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system.
Lee SW; Yun MH; Jeong SW; In CH; Kim JY; Seo MH; Pai CM; Kim SO
J Control Release; 2011 Oct; 155(2):262-71. PubMed ID: 21704664
[TBL] [Abstract][Full Text] [Related]
16. Sterically stabilized liposomes incorporating the novel anticancer agent phospho-ibuprofen (MDC-917): preparation, characterization, and in vitro/in vivo evaluation.
Mattheolabakis G; Nie T; Constantinides PP; Rigas B
Pharm Res; 2012 Jun; 29(6):1435-43. PubMed ID: 22072052
[TBL] [Abstract][Full Text] [Related]
17. Oleanolic acid liposomes with polyethylene glycol modification: promising antitumor drug delivery.
Gao D; Tang S; Tong Q
Int J Nanomedicine; 2012; 7():3517-26. PubMed ID: 22848175
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan.
Riviere K; Kieler-Ferguson HM; Jerger K; Szoka FC
J Control Release; 2011 Aug; 153(3):288-96. PubMed ID: 21600250
[TBL] [Abstract][Full Text] [Related]
19. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.
Hao YL; Deng YJ; Chen Y; Wang KZ; Hao AJ; Zhang Y
J Pharm Pharmacol; 2005 Oct; 57(10):1279-87. PubMed ID: 16259756
[TBL] [Abstract][Full Text] [Related]
20. Long-circulating liposome-encapsulated ganciclovir enhances the efficacy of HSV-TK suicide gene therapy.
Kajiwara E; Kawano K; Hattori Y; Fukushima M; Hayashi K; Maitani Y
J Control Release; 2007 Jul; 120(1-2):104-10. PubMed ID: 17509714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
